The Roche-Syapse collaboration to develop analytics programs may enable health systems to measure the impact of precision therapies, said Damon Hostin, CEO of the Precision Medicine Alliance.
Syapse and Roche are working on building software that would allow health systems to incorporate real-world evidence into Syapse's platform in an effort to develop true clinical decision support for precision therapies.
With a month to go before his Dec. 1 start date as president of MD Anderson Cancer Center, Peter Pisters reflected on the challenges that await him in Houston.
When Eric Karlson's lymphoma went into complete regression in 2009, Steven Rosenberg and James Kochenderfer knew they were making history—for the first time, they had cured a patient by using genetically modified cell therapy, specifically, anti-CD19 CAR-T cells.
It may not be possible to point to definitive causes of the turnover in the executive offices of top academic cancer centers. However, the job of a center director is changing, said Robert Ferris, director of the University of Pittsburgh UPMC Hillman Cancer Center.